结肠腺癌染色质调控因子预后签名开发与验证表1

数据集获取（Figshare）

• 源站标题：Table1_Development and validation of a chromatin regulator prognostic signature in colon adenocarcinoma.XLSX
• DOI：10.3389/fgene.2022.986325.s001
• 发布日期：2022-11-23
• 文件数：1 个
• 文件总体积：11.29 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table1_Development_and_validation_of_a_chromatin_regulator_prognostic_signature_in_colon_adenocarcinoma_XLSX/21607242

命令行下载

curl -L -o "Table1_Development and validation of a chromatin regulator prognostic signature in colon adenocarcinoma.XLSX" "https://ndownloader.figshare.com/files/38298600"

文件清单

• Table1_Development and validation of a chromatin regulator prognostic signature in colon adenocarcinoma.XLSX（11.29 KB）

文件总体积 11.29 KB（源站 API 实测）。

数据说明

Aberrant expression of chromatin regulators (CRs) could lead to the development of various diseases including cancer. However, the biological function and prognosis role of CRs in colon adenocarcinoma (COAD) remains unclear. We performed the clustering analyses for expression profiling of COAD downloaded from The Cancer Genome Atlas. We developed a chromatin regulator prognostic model, which was validated in an independent cohort data. Time-intendent receiver operating characteristics curve was used to evaluate predict ability of model. Univariate and multivariate cox regression were used to assess independence of risk score. Nomogram was established to assess individual risk. Gene ontology, and Kyoto Encyclopedia of genes and genomes, gene set variation analysis and gene set enrichment analysis were performed to explore the function of CRs. Immune infiltration and drug sensitivity were also performed to assess effect of CRs on treatment in COAD. COAD can be separated into two subtypes with different clinical characteristics and prognosis. The C2 had elevated immune infiltration levels and low tumor purity. Using 12 chromatin regulators, we developed and validated a prognostic model that can predict the overall survival of COAD patients. We built a risk score that can be an independent prognosis predictor of COAD. The nomogram score system achieved the best predict ability and were also confirmed by decision curve analysis. There were significantly different function and pathway enrichment, immune infiltration levels, and tumor mutation burden between high-risk and low-risk group. The external validation data also indicated that high-risk group had higher stable disease/progressive disease response rate and poorer prognosis than low-risk group. Besides, the signature genes included in the model could cause chemotherapy sensitivity to some small molecular compounds. Our integrative analyses for chromatin regulators could provide new insights for the risk management and individualized treatment in COAD.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fgene.2022.986325.s001（source: https://frontiersin.figshare.com/articles/dataset/Table1_Development_and_validation_of_a_chromatin_regulator_prognostic_signature_in_colon_adenocarcinoma_XLSX/21607242）。